BEKINDA® (RHB-102) is a proprietary, oral, extended-release (24 hours), once-daily pill formulation of the antiemetic drug ondansetron, targeting multiple gastrointestinal indications.

Ondansetron is a 5-HT3 (serotonin) receptor antagonist which is marketed under various trade names including GSK’s Zofran®. 5-HT3 receptor antagonists are considered the most effective and significant class of drugs in prevention of nausea and vomiting.

BEKINDA® is currently the only once-daily oral formulation of ondansetron, and may be the first to reach the U.S. and European market.

BEKINDA® is being developed for several indications :

  • Gastroenteritis and Gastritis: positive results from a Phase III clinical study in in the U.S.
  • IBS-D (diarrhea-predominant irritable bowel syndrome): positive results from a Phase II clinical study in the U.S.